MARKET

OPK

OPK

OPKO Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.690
+0.260
+7.58%
After Hours: 3.730 +0.04 +1.08% 19:59 09/30 EDT
OPEN
3.560
PREV CLOSE
3.430
HIGH
3.740
LOW
3.535
VOLUME
14.58M
TURNOVER
--
52 WEEK HIGH
6.47
52 WEEK LOW
1.117
MARKET CAP
2.47B
P/E (TTM)
-11.3225
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Implied Volatility Surging for OPKO (OPK) Stock Options
Investors need to pay close attention to OPKO (OPK) stock based on the movements in the options market lately.
Zacks · 14h ago
OPKO Health Initiates Mid-Stage Study on Coronavirus Therapy
OPKO Health (OPK) is developing its marketed drug, Rayaldee, as a potential treatment for patients with mild-to-moderate COVID-19.
Zacks · 09/16 14:25
Opko Launches Phase 2 Trial Of Covid Treatment Rayaldee; Street Bullish
Opko Health announced the initiation of a Phase 2 trial of Rayaldee as a treatment for mild-to-moderate COVID-19. After rising in the pre-market trading hours, Opko stock was down 0.63% at the close on Tuesday.Opko Health’s (OPK) Rayaldee is an extended-release oral formulation of calcifediol, a prohormone
SmarterAnalyst · 09/16 09:48
OPKO Health (OPK) Stock Sinks As Market Gains: What You Should Know
OPKO Health (OPK) closed at $3.15 in the latest trading session, marking a -0.63% move from the prior day.
Zacks · 09/15 21:45
Opko Shares Climb on Phase 2 Trial of Coronavirus Treatment
Opko plans to enroll about 160 people in a Phase 2 double-blind trial of a coronavirus treatment candidate.
TheStreet.com · 09/15 14:05
Shares of Okpo Health jump on plans to test vitamin D drug in COVID-19 patients
Shares of Opko Health undefined were up 3.8% in premarket trading on Tuesday after the company said it is testing Rayaldee as a treatment for...
MarketWatch · 09/15 12:29
OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients
MIAMI, Sept. 15, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces the initiation of a Phase 2 trial with RAYALDEE® as a treatment for mild-to-moderate COVID-19.  The trial, “A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of RAYALDEE (calcifediol
GlobeNewswire · 09/15 12:00
Does OPKO Health's (NASDAQ:OPK) CEO Salary Compare Well With Industry Peers?
This article will reflect on the compensation paid to Phil Frost who has served as CEO of OPKO Health, Inc...
Simply Wall St. · 09/08 18:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OPK. Analyze the recent business situations of OPKO Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OPK stock price target is 8.00 with a high estimate of 10.00 and a low estimate of 6.50.
EPS
Institutional Holdings
Institutions: 303
Institutional Holdings: 208.07M
% Owned: 31.06%
Shares Outstanding: 669.83M
TypeInstitutionsShares
Increased
56
44.42M
New
75
5.31M
Decreased
42
11.80M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.51%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Chairman/Chief Executive Officer/Director
Phillip Frost
Vice Chairman/Chief Technology Officer/Director
Jane Hsiao
Chief Financial Officer/Senior Vice President/Chief Accounting Officer/Treasurer
Adam Logal
Corporate Executive/Director
Jon Cohen
Senior Vice President
Akhtar Ashfaq
Corporate Executive
Charles Bishop
Other
Thomas Nusbickel
Corporate Executive
Tony Cruz
Corporate Executive
Geoff Monk
Executive Vice President/Director
Steven Rubin
Independent Director
Robert Fishel
Independent Director
Anthony Japour
Independent Director
Richard Krasno
Independent Director
Richard Lerner
Independent Director
John Paganelli
Independent Director
Richard Pfenniger
Independent Director
Alice Yu
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OPK
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Opko Health Inc. stock information, including NASDAQ:OPK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OPK stock methods without spending real money on the virtual paper trading platform.